S. Aureus Screening and Decolonization

MRSA Infection of Postoperative Wound Clinical Trial

Official title:

Effectiveness of Screening and Decolonization of S. Aureus in Surgery Outpatients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02182115
• Other study ID #: 1R03HS022912-01
• Secondary ID: 1R03HS022912-01
• Status: Completed
• Phase: Phase 4
• Start date: July 2014
• Est. completion date: August 2016

Study information

• Verified date: November 2019
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Staphylococcus aureus (SA) healthcare-associated infections (HAI) cause significant morbidity and mortality. SA causes 15% of all HAI and 30% of surgical site infections (SSIs). Each year over 40 million Americans undergo operations, 1-10% of whom will acquire SSIs. Such infections double the length of hospitalization and risk of dying, and increase U.S. health care costs by $5-10 billion/year. We need effective interventions to prevent SSIs caused by either methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) strains. Nasal carriers of SA (25-30% of adults) have a 2-14 times greater risk than non-carriers of acquiring an SA SSI. A potential prevention approach is routine pre-operative screening of patients, followed by decolonization of identified SA carriers.

Description:

The long term goal of this research is to help reduce the incidence of SSIs caused by SA, both MSSA and MRSA strains. This will help improve the safety and effectiveness of health care for Americans. Achievement of this goal requires that we first address the following critical knowledge gaps: (i) which surgical patients should be screened pre-operatively; (ii) which body site(s) should be screened for optimal SA detection, and (iii) which decolonization approach is optimal for outpatient use. The goal of this study is to conduct the research needed to determine pre-operative SA carriage rates (including by strain type and site of carriage), to evaluate the practicality (adherence, cost) of a SA decolonization protocol that is self-administered by patients at home. We are conducting randomized clinical trial (RCT) of the efficacy of nasal mupirocin ointment, chlorhexidine gluconate (CHG) mouth rinse, and CHG pre-operative bathing, as performed by the patient at home for 5 days pre-operatively. This protocol will be compared with the current standard of care, usually 1-2 showers with an antiseptic soap before the procedure. Briefly, the aims are as follows:

Aim 1: Determine the efficacy of a novel decolonization protocol, compared with standard of care, for eradicating SA carriage pre-operatively in surgery out-patients. We hypothesize that the SA eradication rate will be 2-3 times higher in the intervention arm compared with the standard of care arm.

Aim 2: Obtain data to inform sample size calculations and cost estimates for a future trial to prevent SSIs, determine screening requirements, and assess treatment adherence. We will: determine the proportion of pre-operative patients who are SA carriers and the sites of carriage, by SA type, determine adherence to the study intervention and standard of care, reasons for non-compliance, and gather cost data to provide preliminary evidence of potential cost-effectiveness of the intervention.

Aim 3: Identify risk factors (demographic, medical) for SA carriage. Gather preliminary data on SSIs in study subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patient who are 18 years and older, able to give informed consent and willing to complete the study decolonization protocol.

• Surgery must be scheduled 2 weeks in the future to allow completion of the study protocol prior to the scheduled operation.

• Patients will be admitted from home the day of the surgery or have the surgery done on an outpatient basis.

Exclusion Criteria:

• Currently on antibiotic therapy, allergy to mupirocin or CHG.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• MRSA Infection of Postoperative Wound
• Wound Infection
• Wound Infection Due to Staphylococcus Aureus
• Wounds and Injuries

Intervention

Drug:
• antiseptic bundle
Chlorhexidine gluconate liquid soap for bathing daily. Chlorhexidine gluconate mouthrinse to use twice daily. Nasal mupirocin to apply twice daily.
• standard of care
Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.

Locations

Country	Name	City	State
United States	University of Minnesota Medical Center	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Minnesota	Agency for Healthcare Research and Quality (AHRQ)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested.	Participants with no SA post-treatment, proportion (%) of participants in each study arm that had no SA detected on the post-treatment cultures from the 4 body sites sampled with swab cultures.	Immediately prior to surgery patients are swabbed again at the 4 body sites to see if SA is present or not.